Sharon Benoit joins INC Research

The contract research organisation INC Research has appointedSharon Benoit principal strategist for infectious disease. She will provide strategic and development consultation to pharmaceutical customers and lead the CRO's virology teams in Phase I-IV trials. Ms Benoit has more than 20 years' experience in virology drug development, with particular focus on HIV and hepatitis. She most recently founded and served as the president of another CRO, and has also held clinical management positions at Glaxo Research Institute, Burroughs Wellcome and the Research Triangle Park Institute.

The contract research organisation INC Research has appointedSharon Benoit principal strategist for infectious disease. She will provide strategic and development consultation to pharmaceutical customers and lead the CRO's virology teams in Phase I-IV trials. Ms Benoit has more than 20 years' experience in virology drug development, with particular focus on HIV and hepatitis. She most recently founded and served as the president of another CRO, and has also held clinical management positions at Glaxo Research Institute, Burroughs Wellcome and the Research Triangle Park Institute.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By 

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapy Areas

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.